Adult: Available preparations:
Triprolidine 0.938 mg and pseudoephedrine 10 mg per mL
2.67 mL 6 hourly. Max: 4 doses in 24 hours.
Triprolidine 1.25 mg and pseudoephedrine 30 mg per 5 ml
10 mL 4-6 hrly. Max: 4 doses in 24 hours.
Triprolidine 2.5 mg and pseudoephedrine 60 mg
1 tab 4-6 hourly. Max: 4 doses in 24 hours. Child: Available preparations:
Triprolidine 0.938 mg and pseudoephedrine 10 mg per mL 6-<12 years 1.33 mL 6 hourly. Max: 4 doses in 24 hours; ≥12 years Same as adult dose.
Triprolidine 1.25 mg and pseudoephedrine 30 mg per 5 ml 6-<12 years 5 mL 4-6 hourly. Max: 4 doses in 24 hours; ≥12 years Same as adult dose.
Triprolidine 2.5 mg and pseudoephedrine 60 mg 6-<12 years 1/2 tab 4-6 hourly. Max: 4 does in 24 hours; ≥12 years Same as adult dose.
Severe hypertension, severe coronary artery disease. Concurrent or within 14 days of MAOI use.
Patient with CV disease, diabetes mellitus, increased intraocular pressure or glaucoma, prostatic hyperplasia, urinary obstruction, respiratory disease, thyroid dysfunction. Moderate to severe renal and severe hepatic impairment. Treatment with cold medicines in children should be considered carefully due to potential risks and limited evidence of efficacy. Pregnancy and lactation.
Significant: CNS depression, urinary retention. Cardiac disorders: Tachycardia. Gastrointestinal disorders: Dry mouth, abdominal pain, diarrhoea, nausea. General disorders and admin site conditions: Fatigue. Musculoskeletal and connective tissue disorders: Arthralgia, weakness. Nervous system disorders: Dizziness, drowsiness, excitement. Psychiatric disorders: Sleep disturbance, depression, hallucinations, nervousness. Respiratory, thoracic and mediastinal disorders: Pharyngitis, thickening of bronchial secretion. Skin and subcutaneous tissue disorders: Rash.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Symptoms: Drowsiness, lethargy, dizziness, ataxia, weakness, difficulty with micturition, dry skin, tachycardia, hypertension, high fever, hyperactivity, irritability, seizures and respiratory depression. Management: Supportive treatment. May perform gastric lavage up to 3 hours after ingestion. Acid diuresis or dialysis may be helpful in pseudoephedrine elimination.
Increased pharmacological effect with CNS depressants.
Pseudoephedrine: May decrease pharmacological effect of antihypertensive agents that interfere with sympathetic activity (e.g. methyldopa, guanethidine). Potentially Fatal: Hypertensive crisis may result when pseudoephedrine is given with MAOIs.
Triprolidine: May react to skin test antigen, suppressing the wheal and flare reactions.
Pseudoephedrine: May cause false-positive result with urine detection of amphetamine.
Description: Triprolidine, an alkylamine derivative, is a potent competitive histamine H1-receptor antagonist hence, inhibiting the ability of histamine to combine with its receptor sites and exert its usual effects on target cells.
Pseudoephedrine is a sympathomimetic agent which has a decongestant action on the nasal mucosa. It directly stimulates α- and β- adrenergic receptors thereby causing vasoconstriction of respiratory mucosa, relaxation of bronchial muscles and increased heart rate and contractility. Onset: Within 1-2 hours (antihistaminic effects); within 30 minutes (decongestant effects). Duration: ≥8 hours (antihistaminic effects); ≥4 hours (decongestant effects). Pharmacokinetics: Absorption: Triprolidine: Time to peak serum concentration: Approx 2 hours.
Pseudoephedrine: Readily absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours. Distribution: Enters breast milk (in small amounts). Metabolism: Triprolidine: Metabolised extensively in the liver. Excretion: Triprolidine: Mainly via urine (approx 1% as unchanged drug). Elimination half-life: Approx 3.2 hours.
Pseudoephedrine: Mainly via urine (mainly as unchanged drug and some as active metabolite). Elimination half-life: Approx 5-8 hours.
R01BA52 - pseudoephedrine, combinations ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
Anon. Triprolidine and Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/08/2018.Anon. Triprolidine Hydrochloride. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 09/08/2018.Buckingham R (ed). Pseudoephedrine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2018.Buckingham R (ed). Triprolidine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2018.Ed-A-Hist Pse Tablet, Coated (Edwards Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/08/2018.Silafed Syrup (Lannett Company, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/08/2018.